Quantitative and qualitative comparison of virulence traits, including murine lethality, among different M types of group A streptococci

Journal of Infectious Diseases

Volumn 187, Issue 12, 2003, Pages 1876-1887

  Miyoshi Akiyama, Tohru ^a   Zhao, Jizi ^a   Kikuchi, Ken ^a   Kato, Hidehito ^a   Suzuki, Rieko ^c   Endoh, Miyoko ^b   Uchiyama, Takehiko ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF PUBLIC HEALTH   (Japan)

^c KANAGAWA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE; STREPTOLYSIN O; SUPERANTIGEN;

ANTIGEN FUNCTION; ARTICLE; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; CONTROLLED STUDY; ENZYME ACTIVITY; GENE IDENTIFICATION; GENETIC ANALYSIS; HUMAN; LETHALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEPTIC SHOCK; SEROTYPE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION;

EID: 0038577966     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/375348     Document Type: Article

References (44)

1. Stevens DL. Invasive group A streptococcus infections. Clin Infect Dis 1992; 14:2-11.
2. Cunningham MW. Streptococcal sequelae and molecular mimicry. In: Cunningham MW, Fujinami RS, eds. Effects of microbes on the immune system. Philadelphia: Lippincott, Williams & Wilkins, 2000: 123-49.
3. Holm SE, Norrby A, Bergholm AM, Norgren M. Aspects of pathogenesis of serious group A streptococcal infections in Sweden, 1988-1989. J Infect Dis 1992; 166:31-7.
4. Efstratiou A, George RC, Gaworzewska ET, et al. Group A streptococcal invasive disease in England and Wales. Adv Exp Med Biol 1997; 418:207-10.
5. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Englender SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shocklike syndrome: a retrospective population-based study. JAMA 1993; 269:384-9.
6. Murakami J, Kawabata S, Terao Y, et al. Distribution of emm genotypes and superantigen genes of Streptococcus pyogenes isolated in Japan, 1994-9. Epidemiol Infect 2002; 128:397-404.
7. Chaussee MS, Liu J, Stevens DL, Ferretti JJ. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections. J Infect Dis 1996; 173:901-8.
8. Nakashima K, Ichiyama S, Iinuma Y, et al. A clinical and bacteriologic investigation of invasive streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints. Clin Infect Dis 1997; 25:260-6.
9. Haukness HA, Tanz RR, Thomson RBJ, et al. The heterogeneity of endemic community pediatric group a streptococcal pharyngeal isolates and their relationship to invasive isolates. J Infect Dis 2002; 185:915-20.
10. Efstratiou A. Group A streptococci in the 1990s. J Antimicrob Chemother 2000; 45:4(Suppl):3-12.
11. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13:470-511.
12. Shiseki M, Miwa K, Nemoto Y, et al. Comparison of pathogenic factors expressed by group A Streptococci isolated from patients with streptococcal toxic shock syndrome and scarlet fever. Microb Pathog 1999; 27:243-52.
13. Sambrook J, Russell DW, eds. Molecular cloning. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001.
14. Finney DJ. Probit analysis. Cambridge: Cambridge University, Press, 1978.
15. Inagaki Y, Watanabe H. Detection of spe genes by PCR. In: Watanabe H, Shimizu Y, eds. Severe invasive streptococcal infections. Tokyo: Kindai Syuppan, 1997:193-7.
16. Kansal RG, McGeer A, Low DE, Norrby-Teglund A, Kotb M. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect Immun 2000; 68: 6362-9.
17. Moses AE, Wessels MR, Zalcman K, et al. Relative contributions of hyaluronic acid capsule and M protein to virulence in a mucoid strain of the group A Streptococcus. Infect Immun 1997; 65:64-71.
18. Stevens DL, Salmi DB, McIndoo ER, Bryant AE. Molecular epidemiology of nga and NAD glycohydrolase/ADP-ribosyltransferase activity among streptococcus pyogenes causing streptococcal toxic shock syndrome. J Infect Dis 2000; 182:1117-28.
19. Cleary PP, Kaplan EL, Handley JP, et al. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s. Lancet 1992; 339: 518-21.
20. Musser JM, Kapur V, Kanjilal S, et al. Geographic and temporal distribution and molecular characterization of two highly pathogenic clones of Streptococcus pyogenes expressing allelic variants of pyrogenic exotoxin A (scarlet fever toxin). J Infect Dis 1993; 167:337-46.
21. Uchiyama T, Yan XJ, Imanishi K, Yagi J. Bacterial superantigens - mechanism of T cell activation by the superantigens and their role in the pathogenesis of infectious diseases. Microbiol Immunol 1994; 38: 245-56.
22. Schlieve PM, Kotb MY, Stevens DL. Streptococcal superantigens: streptococcal toxic shock syndrome: effects of microbes on the immune system. Philadelphia: Lippincott, Williams & Wilkins, 2000; 25-39.
23. Papageorgiou AC, Acharya KR. Microbial superantigens: from structure to function. Trends Microbiol 2000; 8:369-75.
24. Reichardt W. Streptococcus pyogenes. Contrib Microbiol 2001; 8:90-101.
25. Limbago B, Penumalli V, Weinrick B, Scott JR. Role of streptolysin O in a mouse model of invasive group A streptococcal disease. Infect Immun 2000; 68:6384-90.
26. Kobayashi S, Hamada A. Relationship of type specific M antigen content, streptolysin O titer, serological M type and proteinase production of group A streptococci isolated from the patients of scarlet fever. Kansenshogaku Zasshi 1982; 56:20-5.
27. Alouf JE, Geoffroy C. Production, purification, and assay of streptolysin O. Methods Enzymol 1988; 165:52-59.
28. Madden JC, Ruiz N, Caparon M. Cytolysin-mediated translocation (CMT): a functional equivalent of type III secretion in gram-positive bacteria. Cell 2001; 104:143-52.
29. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci USA 1991;88:8317-21.
30. Dale JB, Washburn RG, Marques MB, Wessels MR. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun 1996;64:1495-501.
31. Kawabata S, Kuwata H, Nakagawa I, Morimatsu S, Sano K, Hamada S. Capsular hyaluronic acid of group A streptococci hampers their invasion into human pharyngeal epithelial cells. Microb Pathog 1999; 27:71-80.
32. Stevens DL, Tanner MH, Winship J, et al. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med 1989;321:1-7.
33. Muotiala A, Seppala H, Huovinen P, Vuopio-Varkila J. Molecular comparison of group A streptococci of T1M1 serotype from invasive and noninvasive infections in Finland. J Infect Dis 1997; 175:392-9.
34. Lukomski S, Burns EH, Wyde PR, et al. Genetic inactivation of an extracellular cysteine protease (SpeB) expressed by Streptococcus pyogenes decreases resistance to phagocytosis and dissemination to organs. Infect Immun 1998; 66:771-6.
35. Yu CE, Ferretti JJ. Molecular epidemiologic analysis of the type A streptococcal exotoxin (erythrogenic toxin) gene (speA) in clinical Streptococcus pyogenes strains. Infect Immun 1989; 57:3715-9.
36. Sriskandan S, Moyes D, Buttery LK, et al. Streptococcal pyrogenic exotoxin A release, distribution, and role in a murine model of fasciitis and multiorgan failure due to Streptococcus pyogenes. J Infect Dis 1996; 173:1399-407.
37. Musser JM, Hauser AR, Kim MH, Schlievert PM, Nelson K, Selander RK. Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression. Proc Natl Acad Sci USA 1991; 88:2668-72.
38. Chatellier S, Ihendyane N, Kansal RG, et al. Genetic relatedness and superantigen expression in group A streptococcus serotype M1 isolates from patients with severe and nonsevere invasive diseases. Infect Immun 2000; 68:3523-34.
39. Muller-Alouf H, Proft T, Zollner TM, et al. Pyrogenicity and cytokine-inducing properties of Streptococcus pyogenes superantigens: comparative study of streptococcal mitogenic exotoxin Z and pyrogenic exotoxin A. Infect Immun 2001; 69:4141-5.
40. Karasawa T, Yamakawa K, Tanaka D, Gyobu Y, Nakamura S. NAD(+)-glycohydrolase productivity, of haemolytic streptococci assayed by a simple fluorescent method and its relation to T serotype. FEMS Microbiol Lett 1995; 128:289-92.
41. DelVecchio A, Maley M, Currie BJ, Sriprakash KS. NAD-glycohydrolase production and speA and speC distribution in group A streptococcus (GAS) isolates do not correlate with severe GAS diseases in the Australian population. J Clin Microbiol 2002; 40:2642-4.
42. Boulnois GJ, Roberts IS. Genetics of capsular polysaccharide production in bacteria. Curr Top Microbiol Immunol 1990; 150:1-18.
43. Ashbaugh CD, Warren HB, Carey VJ, Wessels MR. Molecular analysis of the role of the group A streptococcal cysteine protease, hyaluronic acid capsule, and M protein in a murine model of human invasive soft-tissue infection. J Clin Invest 1998; 102:550-60.
44. Johnson DR, Kaplan EL. A review of the correlation of T-agglutination patterns and M-protein typing and opacity factor production in the identification of group A streptococci. J Med Microbiol 1993; 38:311-5.